| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Death-associated protein 1, DAP-1, DAP, DAP1, Death-Associated Protein. |
| Concentration | |
| Expression System | |
| Form | Sterile Filtered clear solution. |
| Formulation | |
| Product Type | |
| Protein Length | |
| Protein Size | |
| Purity | |
| Source | Escherichia Coli. |
| Species | |
| Storage | |
| Target |
Recombinant Human Death-Associated Protein is supplied as a recombinant protein for in vitro research use.
Background
Death-Associated Protein (DAP) is a proline-rich protein. DAP, which is a negative regulator of autophagy, takes part in the mediation of IFN-gamma-induced cell death.
Product format
Provided as a recombinant protein suitable for in vitro workflows such as binding studies, screening, and assay development. Refer to the specifications table for expression format and molecular properties.
What is the purity of Recombinant Human Death-Associated Protein (Human)?
What buffer / formulation is this protein supplied in?
How should Recombinant Human Death-Associated Protein (Human) be stored?
What expression system was used to produce this protein?
Is this protein approved for clinical or in vitro diagnostic use?
Can I request a custom size, tag variant, or formulation?
Can’t Find What You’re Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
